A pair of kidney-focused developments pushed mineralocorticoid and drug-safety questions to the forefront. In the largest non-diabetic chronic kidney disease trial, Phase III FIND-CKD reported that finerenone slowed kidney decline and reduced cardiovascular risk, extending evidence for mineralocorticoid receptor blockade beyond diabetes populations. At the same time, new research presented at the European Renal Association Congress raised concerns about a widely used blood-pressure medication class worsening kidney outcomes in people with type 2 diabetes—highlighting that guideline-standard therapies may need tighter patient stratification. Together, the updates reinforce how nephrology care is increasingly shaped by balancing renal endpoints with cardiovascular protection while scrutinizing comparative safety in real-world comorbidity settings.